transitional cell carcinoma (Cancer)
Information
- Disease name
- transitional cell carcinoma
- Disease ID
- DOID:2671
- Description
- "A carcinoma that derives_from transitional epithelial cells." [url:http\://en.wikipedia.org/wiki/Transitional_cell_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT02420847 | Active, not recruiting | Phase 1/Phase 2 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | July 3, 2015 | December 31, 2025 |
| NCT06462001 | Active, not recruiting | Phase 3 | BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer | December 10, 2020 | December 1, 2026 |
| NCT00173862 | Completed | Phase 2 | Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC | May 2000 | June 2006 |
| NCT00216801 | Completed | Relationship of Ochratoxin A to Upper Urologic Cancers | September 2005 | April 2007 | |
| NCT00389155 | Completed | Phase 2/Phase 3 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | January 2007 | January 2008 |
| NCT00612326 | Completed | Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging | June 2004 | March 2008 | |
| NCT00623831 | Completed | Phase 1 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | May 2007 | May 2013 |
| NCT00633789 | Completed | Phase 2 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | June 2008 | December 2012 |
| NCT00683059 | Completed | Phase 2 | Single Agent Abraxane as Second Line Therapy in Bladder Cancer | March 2008 | June 2012 |
| NCT00714025 | Completed | Phase 2 | A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy | November 2008 | January 2012 |
| NCT00880334 | Completed | Phase 2 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | September 2006 | May 2015 |
| NCT01103544 | Completed | JAVLOR® Online Non-Interventional Trial | April 2010 | August 2013 | |
| NCT01395225 | Completed | Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer | August 2011 | December 2013 | |
| NCT02109328 | Completed | Phase 2 | Alisertib in Chemotherapy-pretreated Urothelial Cancer | August 28, 2014 | October 12, 2016 |
| NCT00101608 | Completed | Phase 2 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | January 2005 | April 2007 |
| NCT00154687 | Completed | Phase 2 | Weekly TP-HDFL in the Treatment of Advanced TCC | October 2000 | December 2004 |
| NCT01668459 | Completed | Phase 2/Phase 3 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel | January 2013 | November 2017 |
| NCT00070070 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas | October 28, 2003 | September 30, 2013 |
| NCT02160600 | Completed | N/A | Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | April 2014 | December 2016 |
| NCT02581982 | Completed | Phase 2 | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | April 6, 2016 | December 19, 2022 |
| NCT03256877 | Completed | Detecting Transitional Cell Carcinoma From Haematuria | October 18, 2016 | May 16, 2019 | |
| NCT04878250 | Not yet recruiting | Phase 2 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder | June 2021 | January 2025 |
| NCT04811846 | Recruiting | N/A | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | March 14, 2021 | August 2025 |
| NCT03927573 | Terminated | Phase 1 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | April 15, 2019 | June 28, 2023 |
| NCT02887248 | Terminated | Phase 2 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | January 12, 2017 | May 1, 2020 |
| NCT01215136 | Terminated | Phase 2 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 2010 | April 24, 2018 |
| NCT01310803 | Terminated | Phase 3 | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | May 2011 | January 2012 |
| NCT01438112 | Terminated | Phase 2/Phase 3 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer | March 2014 | June 2016 |
| NCT05052372 | Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | November 21, 2021 | December 20, 2022 | |
| NCT03296306 | Unknown status | Phase 3 | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma | September 2016 | February 2022 |
| NCT03193788 | Unknown status | Phase 3 | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy | January 2017 | June 2020 |
| NCT03219775 | Unknown status | Phase 2 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma | July 6, 2017 | February 18, 2023 |
| NCT02471547 | Unknown status | N/A | Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT | January 2016 | January 2019 |
| NCT03896958 | Unknown status | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | March 21, 2019 | March 12, 2024 | |
| NCT04179110 | Withdrawn | Phase 2 | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | September 18, 2020 | June 15, 2023 |
| NCT04006691 | Withdrawn | Phase 3 | Efficacy and Safety of UGN-101 in Recurrent Patients | October 1, 2019 | March 31, 2020 |
| NCT00696007 | Withdrawn | Phase 2 | Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer | April 2008 | April 2010 |
| NCT03238664 | Withdrawn | N/A | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | January 22, 2018 | January 22, 2020 |
- Disase is a (Disease Ontology)
- DOID:305
- Cross Reference ID (Disease Ontology)
- GARD:7794
- Cross Reference ID (Disease Ontology)
- ICDO:8120/3
- Cross Reference ID (Disease Ontology)
- MESH:D002295
- Cross Reference ID (Disease Ontology)
- NCI:C2930
- Cross Reference ID (Disease Ontology)
- NCI:C6783
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:118287003
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:27090000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0007138
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0334265
- Exact Synonym (Disease Ontology)
- transitional carcinoma
- Exact Synonym (Disease Ontology)
- transitional cell tumor
- Exact Synonym (Disease Ontology)
- urothelial cell carcinoma
- Disase Synonym (Disease Ontology)
- transitional cell neoplasm